Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorErasme University Hospital
About this trial
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
Eligibility criteria
Qualifiers
Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines
Disqualifiers
Pregnant or nursing patients
Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
Patients with an active lung neoplasm or any active neoplasm for blood samples
Trial design
Treatments tested in this trial
- FAPI PET/CT
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov